| abstract |
The use of a compound of formula I <IMAGE> in which R1, R2 and R3 are N or CH, X1 and X2 are hydrogen, hydroxy, or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclyl group and Z1 and Z2 are hydrogen, hydroxy, keto (=O), or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclyl group or one of Z1 and X1 and Z2 and X2 form a second bond of a double bond at the 1,6 or 2,3 positions with the proviso that at least one of the groupings R1 Z1 X1 R2 Z2 X2 and R1 X1 Z2 form a hydroxamate moiety (-N(OH)C(=O)- and B is a 5 or 6 membered ring of formula II or III <IMAGE> in which R4, R5, R6, R7, R8, R9 and R10 are CH or N with the proviso that ring B cannot contain more than 3 ring members which are nitrogen and the ring B may optionally be substituted by one or more of hydroxy, keto (=O), and an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclyl group or a salt thereof formed with a physiologically acceptable organic or inorganic acid, for the manufacture of a medicament for use as an anti-ischaemic agent. |